ClinicalTrials.gg
CompletedNCT02451137Updated Sep 10, 2019Results posted

A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)

A Phase 4 interventional study of Insulin glargine, 300 U/ml and Insulin glargine, 100 U/ml in Diabetes Mellitus, Type 2, sponsored by Sanofi. Completed at 427 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-10.

Sponsored by Sanofi · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
3,304
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 — 4 open to participants now, 6 under way, 1 of them phase 3. Insulin Glargine · Diabetes Mellitus, Type 2.

Enrollment
5th of 175
3,304 · median 253
Started
2015
with 13 others
Phase 4
103 of 176
2 open now
Registered
124th of 176
by date
Lead sponsor
82 of 176
Sanofi

Among the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, this one is the 5th largest by enrollment of the 175 interventional ones that give a count, is one of 14 that started in 2015, is one of 103 in phase 4, and was the 124th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

4 of the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About Insulin Glargine

Insulin Glargine: first FDA approval 2000 (LANTUS SOLOSTAR), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

Primary Objective:

Demonstrate clinical benefit of Toujeo in achieving individualized Healthcare Effectiveness Data and Information Set (HEDIS) glycated hemoglobin (HbA1c) targets (\<8% if age >=65 years or with defined comorbidities or otherwise \<7%) at 6 months without documented symptomatic (Blood Glucose \<=70 mg/deciliter [mg/dL]) and/or severe hypoglycemia at any time of day from baseline to 6 months in uncontrolled insulin naive participants with type 2 diabetes initiating basal insulin therapy in a real world setting.

Secondary Objectives:

Compare Toujeo to other commercially available basal insulins at 6 months after initiating insulin therapy in a real world setting in terms of:

  • Participant persistence with assigned basal insulin therapy.
  • Risk of hypoglycemia including the incidence and rate of documented symptomatic and severe hypoglycemia.
  • Changes in HbA1c, fasting plasma glucose, body weight
  • Differences in participant and provider- reported outcomes (including Diabetes Treatment Satisfaction Questionnaire Status and Change Versions (DTSQs) and (DTSQc), Hypoglycemia Patient Questionnaire, and participant and provider reported Global Effectiveness Scale (GES).
  • Healthcare resource utilization including hospitalizations and emergency department or other provider visits and healthcare costs.
Read the detailed description

The total study duration per patient will be up to 53 weeks, consisting of a 1-week screening period at the site, a 26-week treatment period, and a 26-week extension period.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with Type 2 Diabetes Mellitus (T2DM), as defined by the American Diabetes Association/World Health Organization, diagnosed for at least 1 year at the time of the screening visit, insufficiently controlled after at least 1 year of treatment with 2 or more of the following: oral agents (metformin, sulfonylureas, thiazolidinediones, dipeptidyl peptidase-4 (DPP4) inhibitors, or sodium-glucose cotransporter 2 (SGLT2) inhibitors) or glucagon-like peptide-1 (GLP-1) receptor agonists approved for daily use with insulin (Victoza, Byetta, Adlyxin).
  • Adult patients who have signed an Form and Health Insurance Portability and Accountability Act (HIPAA) Authorization Form.

Exclusion criteria

Exclusion criteria:

  • \<8.0% or >11.0%.
  • Males or females \<18 years of age.
  • Type 1 diabetes mellitus.
  • Any abnormality identified on physical examination, laboratory tests, or vital signs at the time of screening, or any major systemic disease resulting in short that in the opinion of the Investigator would restrict or limit the participant's successful participation for the duration of the study.
  • Use of any product containing insulin (Lantus, Levemir, Humulin, Novolin, Humalog, Novolog, Apidra, or Afrezza) since the time of diagnosis with T2DM other than temporary use during pregnancy or hospitalization, or short-term use during acute event.
  • Use of oral hypoglycemic agents other than those noted in the inclusion criteria, GLP-1 receptor agonists for weekly use, or any agent (drug, biologic, or device) within 3 months prior to the time of screening.
  • All to commercially available insulin therapy or warnings/precautions of use as displayed in the respective national product labeling for these products.
  • Pregnancy or lactation.
  • Women of with no effective method.

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
3,304 participants (actual)

Study arms

  • Experimental
    Toujeo

    Toujeo® (Insulin glargine, 300 units per millilitre \[U/mL\]) subcutaneous (SC) injection once daily up to Month 12, with or without available participant support program.

    Drug: Insulin glargine, 300 U/ml · Drug: Background Therapy

  • Active comparator
    Standard of Care

    Lantus® (Insulin glargine, 100 U/mL) SC injection administered once daily; or Levemir® (Insulin detemir) SC injection administered either once or twice daily up to Month 12, with or without available participant support program.

    Drug: Insulin glargine, 100 U/ml · Drug: Insulin detemir · Drug: Background Therapy

Interventions

  • DrugInsulin glargine, 300 U/ml

    Drug page: Insulin Glargine

    Pharmaceutical form: solution Route of administration: subcutaneous

    Also known as: Toujeo

  • DrugInsulin glargine, 100 U/ml

    Drug page: Insulin Glargine

    Pharmaceutical form: solution Route of administration: subcutaneous

    Also known as: Lantus

  • Pharmaceutical form: solution Route of administration: subcutaneous

    Also known as: Levemir

  • DrugBackground Therapy

    Anti-diabetic drugs at investigator discretion and consistent with local labeling guidelines for use with insulin.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Individualized Glycated Hemoglobin Target Attainment Per Healthcare Effectiveness Data and Information Set (HEDIS) Criteria Without Documented Symptomatic(Blood Glucose <=70 mg/dL [<=3.9 mmol/L]) and/or Severe Hypoglycemia

    HEDIS criteria: Individualized HbA1c target \<8% if age \>= 65 years or presence of medical comorbidities, or otherwise \<7%. Severe hypoglycaemia was an event in which the participant required the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Documented symptomatic hypoglycaemia was an event during which typical symptoms of hypoglycaemia were accompanied by a measured plasma glucose concentration of \<=70 milligrams per deciliter (mg/dL) (\<=3.9 millimoles per litre \[mmol/L\]). Analysis was performed using all post-baseline data available on the 6 month randomized period (defined as time from randomization up to Day 180 or discontinuation date, whichever comes earlier).

    Time frame: Baseline to Month 6

Secondary outcomes

  1. Change From Baseline in HbA1c at Month 6 and Month 12

    Change in HbA1c was calculated by subtracting baseline value from Month 6 and Month 12 values. Adjusted Least Squares (LS) means and Standard Errors (SE) were obtained using Mixed Effect Model with Repeated Measures (MMRM ) with fixed categorical effects of treatment arm, visit, treatment arm-by-visit interaction, randomization strata of HbA1c target (\<8% / \<7%), SU use (yes/no), GLP-1 RA use (yes/no), as well as baseline HbA1c (as continuous) and baseline HbA1c-by-visit interaction.

    Time frame: Baseline, Month 6, Month 12

  2. Treatment Persistence Measured by Medication Possession Ratio (MPR)

    Treatment persistence was determined based on vendor claims database that would be responsible for managing and administration of the study drugs. Medication use was assessed by MPR and persistence measures based on data collected by the smart card vendor (date of fill or refill and quantity of medication dispensed for 30-day supply). The MPR was assessed based on total number of days of supply divided by the total number of days in 6 or 12 months period.

    Time frame: At Month 6 and Month 12

  3. Percentage of Participants Reaching Individualized HbA1c Target Without Documented Symptomatic <3.0 mmol/L (<54 mg/dL) and/or Severe Hypoglycemia During the 6-Month Randomized Period

    HEDIS criteria for Individualized HbA1c target: \<8% if age \>= 65 years or presence of medical comorbidities, or otherwise \<7%. Severe hypoglycaemia was an event in which the participant required the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Documented symptomatic hypoglycaemia was an event during which typical symptoms of hypoglycaemia were accompanied by a measured plasma glucose concentration of \<54 mg/dL (3.0 mmol/L).

    Time frame: Baseline to Month 6

  4. Percentage of Participants Reaching Individualized HbA1c Target Without Documented Symptomatic <=3.9 mmol/L (<= 70 mg/dL) and <3.0 mmol/L (< 54 mg/dL) and/or Severe Hypoglycemia During the 12-Month Randomized Period

    HEDIS criteria for Individualized HbA1c target: \<8% if age \>= 65 years or presence of medical comorbidities, or otherwise \<7%. Severe hypoglycaemia was an event in which the participant required the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Documented symptomatic hypoglycaemia was an event during which typical symptoms of hypoglycaemia were accompanied by a measured plasma glucose concentration of \<=3.9 mmol/L (\<=70 mg/dL) and \< 3.0 mmol/L (\< 54 mg/dL).

    Time frame: Baseline to Month 12

  5. Change From Baseline in Fasting Plasma Glucose (FPG) at Month 6 and Month 12

    Change in FPG was calculated by subtracting baseline value from Month 6 and Month 12 values. Adjusted LS means and SE were obtained using MMRM model with fixed categorical effects of treatment arm, randomization strata of HbA1c target (\<8% / \<7%), SU use (yes/no), GLP-1 RA use (yes/no), as well as baseline FPG (as continuous) and baseline FPG-by-visit interaction.

    Time frame: Baseline, Month 6, Month 12

  6. Change From Baseline in Body Weight at Month 6 and Month 12

    Adjusted LS means and SE were obtained using MMRM model with fixed categorical effects of treatment arm, visit, treatment arm-by-visit interaction, randomization strata of HbA1c target (\<8% / \<7%), SU use (yes/no), GLP-1 RA use (yes/no), as well as baseline weight (as continuous) and baseline weight-by-visit interaction.

    Time frame: Baseline, Month 6, Month 12

  7. Change From Baseline in Basal Insulin Dose at Month 6 and Month 12

    Change in basal insulin dose was calculated by subtracting baseline value from Month 6 and Month 12 values.

    Time frame: Baseline, Month 6, Month 12

  8. Percentage of Responders (Participants and Provider) Who Reported "Excellent" or "Good" Responses to Global Effectiveness Scale (GES) Question at Month 6, and Month 12

    Participant and Physician (Provider) reported GES for this diabetes study. The GES assessed impact of treatment on scale ranges as: excellent (complete control of diabetes), good (marked improvement of diabetes), moderate (discernible, but limited improvement in diabetes), poor (no appreciable change in diabetes), or worsening of condition (worsening of diabetes). There was no score expressed by numbers and no change measured over the time of the study. Percentage of participants and providers who reported "excellent" or "good" on the GES at Month 6 and Month 12 are reported here.

    Time frame: At Month 6, Month 12

  9. Scores of Total Treatment Satisfaction, Hyperglycemia Perception, and Hypoglycemia Perception From Diabetes Treatment Satisfaction Questionnaire Status Version (DTSQs) at Baseline, Month 6, Month 12

    DTSQs is a validated questionnaire to assess participant's satisfaction with their diabetes treatment. It consists of 8 items, each answered on a Likert scale of 0 to 6. Responses of 6 questions (Items 1, 4, 5, 6, 7 and 8) were summarized to derive total treatment satisfaction score, such that a higher score was indicative of better satisfaction. Total treatment satisfaction score is the sum of items 1, 4-8 scores and ranged from 0 (no satisfaction) to 36 (improvement in treatment satisfaction). Item 2 and Item 3 scores were used for hyperglycemia perception and hypoglycemia perception respectively, where lower scores indicated better health outcome. Perceived frequency of hyperglycemia score (Item 2) and perceived frequency of hypoglycemia score (Item 3) range from 0 (none of the time) to 6 (most of time), where lower scores indicated more satisfaction/better health outcome.

    Time frame: At Baseline, Month 6, Month 12

  10. Scores of Total Treatment Satisfaction, Hyperglycemia Perception, and Hypoglycemia Perception From Diabetes Treatment Satisfaction Questionnaire Change Version (DTSQc) at Month 12

    DTSQc version evaluates the change in treatment satisfaction at Month 12 as compared to the start of the study . It consists of 8 items, each answered on a Likert scale from -3 to +3. The sum of treatment satisfaction scores (items 1, 4, 5, 6, 7,and 8) ranged from score -18 (deterioration in treatment satisfaction) to +18 (improvement in treatment satisfaction). Perceived frequency of hypoglycemia and perceived frequency of hyperglycemia score ranges from score -3 (fewer problems) to +3 (more problems).

    Time frame: At Month 12

  11. Percentage of Participants With Hospitalizations, Emergency Rooms and Specialty Visits From Baseline to Month 6 and Month 12

    Percentage of participants with hospitalizations, emergency room visits, and specialty visits during the 6-month and 12-month randomized period were reported. The 12-month randomized period was defined as the time from randomization up to Day 365 or discontinuation date, whichever comes earlier.

    Time frame: From Baseline to Month 6 and Month 12

  12. Percentage of Participants With at Least One Treatment-Emergent Hypoglycemia Event (Any Time of the Day, Nocturnal) Per Type of Hypoglycaemia During the Month 6 and Month 12 on Treatment Period

    Severe hypoglycaemia was an event in which the participant required the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Documented symptomatic hypoglycaemia was an event during which typical symptoms of hypoglycaemia were accompanied by a measured plasma glucose concentration of \<=70 mg/dL (\<=3.9 mmol/L) or \<54 mg/dL (3.0 mmol/L).

    Time frame: Up to Month 6 and Month 12

07

Results

Posted May 1, 2019

Participant flow

The study was conducted at 427 sites in 2 countries. A total of 4989 participants were screened between 16 June 2015 and 14 July 2017, of which 1684 were screen failures. Screen failures were mainly due to inclusion criteria not met.

Participant flow — Overall Study
MilestoneToujeoStandard of Care
Started16511653
Treated16321626
Safety population16371621
Completed14051355
Not completed246298
Withdrew: Randomized but not treated1927
Withdrew: Adverse event4342
Withdrew: Lack of efficacy49
Withdrew: Participant decision:discontinue insulin4143
Withdrew: Hypoglycemia21
Withdrew: Investigator's decision2319
Withdrew: Lost to follow-up5361
Withdrew: Physician decision65
Withdrew: Sponsor decision1325
Withdrew: Withdrawal by subject4063
Withdrew: Other than specified above23

Outcome measures

PrimaryPercentage of Participants With Individualized Glycated Hemoglobin Target Attainment Per Healthcare Effectiveness Data and Information Set (HEDIS) Criteria Without Documented Symptomatic(Blood Glucose <=70 mg/dL [<=3.9 mmol/L]) and/or Severe Hypoglycemia

HEDIS criteria: Individualized HbA1c target \<8% if age \>= 65 years or presence of medical comorbidities, or otherwise \<7%. Severe hypoglycaemia was an event in which the participant required the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Documented symptomatic hypoglycaemia was an event during which typical symptoms of hypoglycaemia were accompanied by a measured plasma glucose concentration of \<=70 milligrams per deciliter (mg/dL) (\<=3.9 millimoles per litre \[mmol/L\]). Analysis was performed using all post-baseline data available on the 6 month randomized period (defined as time from randomization up to Day 180 or discontinuation date, whichever comes earlier).

Time frame:
Baseline to Month 6
Reported as:
Number · percentage of participants
Percentage of Participants With Individualized Glycated Hemoglobin Target Attainment Per Healthcare Effectiveness Data and Information Set (HEDIS) Criteria Without Documented Symptomatic(Blood Glucose <=70 mg/dL [<=3.9 mmol/L]) and/or Severe Hypoglycemia
percentage of participantsToujeoStandard of Care
Percentage of Participants With Individualized Glycated Hemoglobin Target Attainment Per Healthcare Effectiveness Data and Information Set (HEDIS) Criteria Without Documented Symptomatic(Blood Glucose <=70 mg/dL [<=3.9 mmol/L]) and/or Severe Hypoglycemia31.327.9
Statistical analysis
  • Toujeo vs Standard of Care · Regression, Logistic · p = 0.0308 (Threshold for significance at 0.046 level.) · Odds ratio (or): 1.19 · 95.4% CI 1.01 to 1.39
SecondaryChange From Baseline in HbA1c at Month 6 and Month 12

Change in HbA1c was calculated by subtracting baseline value from Month 6 and Month 12 values. Adjusted Least Squares (LS) means and Standard Errors (SE) were obtained using Mixed Effect Model with Repeated Measures (MMRM ) with fixed categorical effects of treatment arm, visit, treatment arm-by-visit interaction, randomization strata of HbA1c target (\<8% / \<7%), SU use (yes/no), GLP-1 RA use (yes/no), as well as baseline HbA1c (as continuous) and baseline HbA1c-by-visit interaction.

Time frame:
Baseline, Month 6, Month 12
Reported as:
Least squares mean · percentage of HbA1c
Change From Baseline in HbA1c at Month 6 and Month 12
percentage of HbA1cToujeoStandard of Care
Month 6-1.40 ± 0.030-1.36 ± 0.030
Month 12-1.29 ± 0.034-1.24 ± 0.034
SecondaryTreatment Persistence Measured by Medication Possession Ratio (MPR)

Treatment persistence was determined based on vendor claims database that would be responsible for managing and administration of the study drugs. Medication use was assessed by MPR and persistence measures based on data collected by the smart card vendor (date of fill or refill and quantity of medication dispensed for 30-day supply). The MPR was assessed based on total number of days of supply divided by the total number of days in 6 or 12 months period.

Time frame:
At Month 6 and Month 12
Reported as:
Mean · Medication Possession ratio
Treatment Persistence Measured by Medication Possession Ratio (MPR)
Medication Possession ratioToujeoStandard of Care
Month 662.06 ± 26.9863.14 ± 28.42
Month 1258.21 ± 28.8757.82 ± 29.97
SecondaryPercentage of Participants Reaching Individualized HbA1c Target Without Documented Symptomatic <3.0 mmol/L (<54 mg/dL) and/or Severe Hypoglycemia During the 6-Month Randomized Period

HEDIS criteria for Individualized HbA1c target: \<8% if age \>= 65 years or presence of medical comorbidities, or otherwise \<7%. Severe hypoglycaemia was an event in which the participant required the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Documented symptomatic hypoglycaemia was an event during which typical symptoms of hypoglycaemia were accompanied by a measured plasma glucose concentration of \<54 mg/dL (3.0 mmol/L).

Time frame:
Baseline to Month 6
Reported as:
Number · percentage of participants
Percentage of Participants Reaching Individualized HbA1c Target Without Documented Symptomatic <3.0 mmol/L (<54 mg/dL) and/or Severe Hypoglycemia During the 6-Month Randomized Period
percentage of participantsToujeoStandard of Care
Percentage of Participants Reaching Individualized HbA1c Target Without Documented Symptomatic <3.0 mmol/L (<54 mg/dL) and/or Severe Hypoglycemia During the 6-Month Randomized Period37.334.3
SecondaryPercentage of Participants Reaching Individualized HbA1c Target Without Documented Symptomatic <=3.9 mmol/L (<= 70 mg/dL) and <3.0 mmol/L (< 54 mg/dL) and/or Severe Hypoglycemia During the 12-Month Randomized Period

HEDIS criteria for Individualized HbA1c target: \<8% if age \>= 65 years or presence of medical comorbidities, or otherwise \<7%. Severe hypoglycaemia was an event in which the participant required the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Documented symptomatic hypoglycaemia was an event during which typical symptoms of hypoglycaemia were accompanied by a measured plasma glucose concentration of \<=3.9 mmol/L (\<=70 mg/dL) and \< 3.0 mmol/L (\< 54 mg/dL).

Time frame:
Baseline to Month 12
Reported as:
Number · percentage of participants
Percentage of Participants Reaching Individualized HbA1c Target Without Documented Symptomatic <=3.9 mmol/L (<= 70 mg/dL) and <3.0 mmol/L (< 54 mg/dL) and/or Severe Hypoglycemia During the 12-Month Randomized Period
percentage of participantsToujeoStandard of Care
Month 12: <=70 mg/dL26.123.7
Month 12: <54 mg/dL33.029.5
SecondaryChange From Baseline in Fasting Plasma Glucose (FPG) at Month 6 and Month 12

Change in FPG was calculated by subtracting baseline value from Month 6 and Month 12 values. Adjusted LS means and SE were obtained using MMRM model with fixed categorical effects of treatment arm, randomization strata of HbA1c target (\<8% / \<7%), SU use (yes/no), GLP-1 RA use (yes/no), as well as baseline FPG (as continuous) and baseline FPG-by-visit interaction.

Time frame:
Baseline, Month 6, Month 12
Reported as:
Least squares mean · mg/dL
Change From Baseline in Fasting Plasma Glucose (FPG) at Month 6 and Month 12
mg/dLToujeoStandard of Care
Month 6-48.9 ± 1.56-50.4 ± 1.58
Month 12-48.0 ± 1.66-47.3 ± 1.69
SecondaryChange From Baseline in Body Weight at Month 6 and Month 12

Adjusted LS means and SE were obtained using MMRM model with fixed categorical effects of treatment arm, visit, treatment arm-by-visit interaction, randomization strata of HbA1c target (\<8% / \<7%), SU use (yes/no), GLP-1 RA use (yes/no), as well as baseline weight (as continuous) and baseline weight-by-visit interaction.

Time frame:
Baseline, Month 6, Month 12
Reported as:
Least squares mean · kilogram (kg)
Change From Baseline in Body Weight at Month 6 and Month 12
kilogram (kg)ToujeoStandard of Care
Month 61.02 ± 0.1091.14 ± 0.110
Month 121.51 ± 0.1401.40 ± 0.142
SecondaryChange From Baseline in Basal Insulin Dose at Month 6 and Month 12

Change in basal insulin dose was calculated by subtracting baseline value from Month 6 and Month 12 values.

Time frame:
Baseline, Month 6, Month 12
Reported as:
Mean · Unit/kg (U/kg)
Change From Baseline in Basal Insulin Dose at Month 6 and Month 12
Unit/kg (U/kg)ToujeoStandard of Care
Month 60.179 ± 0.2120.183 ± 0.218
Month 120.222 ± 0.2320.224 ± 0.241
SecondaryPercentage of Responders (Participants and Provider) Who Reported "Excellent" or "Good" Responses to Global Effectiveness Scale (GES) Question at Month 6, and Month 12

Participant and Physician (Provider) reported GES for this diabetes study. The GES assessed impact of treatment on scale ranges as: excellent (complete control of diabetes), good (marked improvement of diabetes), moderate (discernible, but limited improvement in diabetes), poor (no appreciable change in diabetes), or worsening of condition (worsening of diabetes). There was no score expressed by numbers and no change measured over the time of the study. Percentage of participants and providers who reported "excellent" or "good" on the GES at Month 6 and Month 12 are reported here.

Time frame:
At Month 6, Month 12
Reported as:
Number · percentage of responders
Percentage of Responders (Participants and Provider) Who Reported "Excellent" or "Good" Responses to Global Effectiveness Scale (GES) Question at Month 6, and Month 12
percentage of respondersToujeoStandard of Care
Percentage of Participants: Month 667.265.6
Percentage of Providers: Month 662.157.7
Percentage of Participants: Month 1264.764.2
Percentage of Providers: Month 1258.856.3
SecondaryScores of Total Treatment Satisfaction, Hyperglycemia Perception, and Hypoglycemia Perception From Diabetes Treatment Satisfaction Questionnaire Status Version (DTSQs) at Baseline, Month 6, Month 12

DTSQs is a validated questionnaire to assess participant's satisfaction with their diabetes treatment. It consists of 8 items, each answered on a Likert scale of 0 to 6. Responses of 6 questions (Items 1, 4, 5, 6, 7 and 8) were summarized to derive total treatment satisfaction score, such that a higher score was indicative of better satisfaction. Total treatment satisfaction score is the sum of items 1, 4-8 scores and ranged from 0 (no satisfaction) to 36 (improvement in treatment satisfaction). Item 2 and Item 3 scores were used for hyperglycemia perception and hypoglycemia perception respectively, where lower scores indicated better health outcome. Perceived frequency of hyperglycemia score (Item 2) and perceived frequency of hypoglycemia score (Item 3) range from 0 (none of the time) to 6 (most of time), where lower scores indicated more satisfaction/better health outcome.

Time frame:
At Baseline, Month 6, Month 12
Reported as:
Mean · score on a scale
Scores of Total Treatment Satisfaction, Hyperglycemia Perception, and Hypoglycemia Perception From Diabetes Treatment Satisfaction Questionnaire Status Version (DTSQs) at Baseline, Month 6, Month 12
score on a scaleToujeoStandard of Care
Total treatment satisfaction score:Baseline26.5 ± 7.026.4 ± 7.1
Total treatment satisfaction score: Month 631.0 ± 5.531.1 ± 5.3
Total treatment satisfaction score: Month 1230.9 ± 6.030.7 ± 6.1
Perceived frequencyof hyperglycemia score:Baseline4.3 ± 1.74.3 ± 1.7
Perceived frequency of hyperglycemia score:Month 62.8 ± 1.72.8 ± 1.7
Perceived frequency of hyperglycemia score:Month122.6 ± 1.72.6 ± 1.7
Perceived frequency of hypoglycemia score:Baseline0.9 ± 1.40.8 ± 1.3
Perceived frequency of hypoglycemia score: Month 60.9 ± 1.31.0 ± 1.4
Perceived frequency of hypoglycemia score:Month 120.9 ± 1.31.0 ± 1.4
SecondaryScores of Total Treatment Satisfaction, Hyperglycemia Perception, and Hypoglycemia Perception From Diabetes Treatment Satisfaction Questionnaire Change Version (DTSQc) at Month 12

DTSQc version evaluates the change in treatment satisfaction at Month 12 as compared to the start of the study . It consists of 8 items, each answered on a Likert scale from -3 to +3. The sum of treatment satisfaction scores (items 1, 4, 5, 6, 7,and 8) ranged from score -18 (deterioration in treatment satisfaction) to +18 (improvement in treatment satisfaction). Perceived frequency of hypoglycemia and perceived frequency of hyperglycemia score ranges from score -3 (fewer problems) to +3 (more problems).

Time frame:
At Month 12
Reported as:
Least squares mean · score on a scale
Scores of Total Treatment Satisfaction, Hyperglycemia Perception, and Hypoglycemia Perception From Diabetes Treatment Satisfaction Questionnaire Change Version (DTSQc) at Month 12
score on a scaleToujeoStandard of Care
Total satisfaction score13.81 ± 0.1513.79 ± 0.15
Perceived frequency of hyperglycemia score0.14 ± 0.050.21 ± 0.05
Perceived frequency of hypoglycemia-0.82 ± 0.05-0.82 ± 0.05
SecondaryPercentage of Participants With Hospitalizations, Emergency Rooms and Specialty Visits From Baseline to Month 6 and Month 12

Percentage of participants with hospitalizations, emergency room visits, and specialty visits during the 6-month and 12-month randomized period were reported. The 12-month randomized period was defined as the time from randomization up to Day 365 or discontinuation date, whichever comes earlier.

Time frame:
From Baseline to Month 6 and Month 12
Reported as:
Number · percentage of participants
Percentage of Participants With Hospitalizations, Emergency Rooms and Specialty Visits From Baseline to Month 6 and Month 12
percentage of participantsToujeoStandard of Care
Hospitalizations: Month 68.17.5
Emergency Room Visits: Month 611.310.3
Specialty Visits: Month 678.374.0
Hospitalizations: Month 129.18.0
Emergency Room Visits: Month 1212.711.1
Specialty Visits: Month 1280.175.9
SecondaryPercentage of Participants With at Least One Treatment-Emergent Hypoglycemia Event (Any Time of the Day, Nocturnal) Per Type of Hypoglycaemia During the Month 6 and Month 12 on Treatment Period

Severe hypoglycaemia was an event in which the participant required the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Documented symptomatic hypoglycaemia was an event during which typical symptoms of hypoglycaemia were accompanied by a measured plasma glucose concentration of \<=70 mg/dL (\<=3.9 mmol/L) or \<54 mg/dL (3.0 mmol/L).

Time frame:
Up to Month 6 and Month 12
Reported as:
Number · percentage of participants
Percentage of Participants With at Least One Treatment-Emergent Hypoglycemia Event (Any Time of the Day, Nocturnal) Per Type of Hypoglycaemia During the Month 6 and Month 12 on Treatment Period
percentage of participantsToujeoStandard of Care
Any hypoglycemia: Any time: Month 628.930.4
Any hypoglycemia: Nocturnal: Month 68.910.0
Any hypoglycemia: Any time: Month 1239.141.8
Any hypoglycemia: Nocturnal: Month 1213.614.9
Severe hypoglycemia: Any time: Month 61.01.0
Severe hypoglycemia:Nocturnal: Month 60.50.6
Documented Symptomatic <=70 mg/dL:Any time:Month 613.914.9
Documented Symptomatic <54 mg/dL:Any time:Month 63.63.1
Documented Symptomatic <=70mg/dL:Nocturnal:Month 64.55.6
Documented Symptomatic <54 mg/dL:Nocturnal:Month 60.80.8
Severe hypoglycemia: Any time: Month 121.21.9
Severe hypoglycemia:Nocturnal: Month 120.50.7
Documented Symptomatic<=70 mg/dL:Any time:Month 1219.920.8
Documented Symptomatic <54 mg/dL:Any time:Month 125.65.6
Documented Symptomatic<=70mg/dL:Nocturnal:Month 126.58.3
Documented Symptomatic <54mg/dL:Nocturnal:Month 121.21.7

Adverse events

Collected over All Adverse Events (AE) were collected from signature of the informed consent form up to the end of study (12 months) regardless of seriousness or relationship to investigational product.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Toujeo7/1,637 (0.4%)161/1,637 (9.8%)0/1,637 (0%)
Standard of Care Basal Insulin4/1,621 (0.2%)165/1,621 (10.2%)0/1,621 (0%)
Most frequent serious events
Showing 10 of 281
Most frequent serious events
EventToujeoStandard of Care Basal Insulin
PneumoniaInfections and infestations10/163714/1621
Coronary Artery DiseaseCardiac disorders10/16379/1621
Non-Cardiac Chest PainGeneral disorders10/16375/1621
Acute Kidney InjuryRenal and urinary disorders8/16379/1621
SepsisInfections and infestations4/16378/1621
Acute Myocardial InfarctionCardiac disorders8/16374/1621
Atrial FibrillationCardiac disorders8/16376/1621
CellulitisInfections and infestations2/16377/1621
Angina PectorisCardiac disorders6/16373/1621
Cardiac Failure CongestiveCardiac disorders6/16374/1621

Baseline characteristics

Analysis was performed on all randomized participants. Participants belonging to more than one race, have been reported under each applicable category.

Age, Continuous
Age, Continuous(years)ToujeoStandard of CareTotal
Mean59.4 ± 10.859.1 ± 11.059.3 ± 10.9
Sex: Female, Male
Sex: Female, Male(Participants)ToujeoStandard of CareTotal
Female7477311478
Male9049221826
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)ToujeoStandard of CareTotal
Hispanic or Latino286305591
Not Hispanic or Latino136513482713
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)ToujeoStandard of CareTotal
Caucasian/White128312992582
Black262238500
Asian/Oriental8395178
American Indian or Alaska Native151227
Native Hawaiian or other Pacific Islander6410
Other121426
Region of Enrollment
Region of Enrollment(Participants)ToujeoStandard of CareTotal
Canada8285167
United States156915683137
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)ToujeoStandard of CareTotal
Mean33.85 ± 7.1433.70 ± 7.2933.77 ± 7.22
Duration of Type 2 Diabetes Mellitus
Duration of Type 2 Diabetes Mellitus(years)ToujeoStandard of CareTotal
Mean11.43 ± 7.4311.16 ± 7.3111.30 ± 7.37
Baseline glycated hemoglobin (HbA1c)
Baseline glycated hemoglobin (HbA1c)(percentage of HbA1c)ToujeoStandard of CareTotal
Mean9.1 ± 0.89.2 ± 0.89.2 ± 0.8
08

Study locations

427 sites
  • Investigational Site Number 840731
    Birmingham, Alabama 35205, United States
  • Investigational Site Number 840305
    Birmingham, Alabama 35211, United States
  • Investigational Site Number 840811
    Birmingham, Alabama 35235, United States
  • Investigational Site Number 840218
    Gulf Shores, Alabama 36542, United States
  • Investigational Site Number 840739
    Guntersville, Alabama 35976, United States
  • Investigational Site Number 840367
    Huntsville, Alabama 35801, United States
  • Investigational Site Number 840130
    Montgomery, Alabama 36104, United States
  • Investigational Site Number 840729
    Montgomery, Alabama 36109, United States
  • Investigational Site Number 840281
    Saraland, Alabama 36571, United States
  • Investigational Site Number 840613
    Sheffield, Alabama 35660, United States
  • Investigational Site Number 840634
    Sheffield, Alabama 35660, United States
  • Investigational Site Number 840654
    Sheffield, Alabama 35660, United States
  • Investigational Site Number 840173
    Phoenix, Arizona 85032, United States
  • Investigational Site Number 840555
    Phoenix, Arizona 85037, United States
  • Investigational Site Number 840805
    Sun City, Arizona 85351, United States
  • Investigational Site Number 840725
    Conway, Arkansas 72034, United States
  • Investigational Site Number 840790
    Jonesboro, Arkansas 72401, United States
  • Investigational Site Number 840699
    Little Rock, Arkansas 72204, United States
  • Investigational Site Number 840528
    Little Rock, Arkansas 72205, United States
  • Investigational Site Number 840079
    Searcy, Arkansas 72143, United States
  • Investigational Site Number 840337
    Bakersfield, California 93304, United States
  • Investigational Site Number 840089
    El Cajon, California 92020, United States
  • Investigational Site Number 840024
    Escondido, California 92025, United States
  • Investigational Site Number 840020
    Fresno, California 93721, United States
  • Investigational Site Number 840470
    Imperial, California 92251, United States
  • Investigational Site Number 840155
    Inglewood, California 90301, United States
  • Investigational Site Number 840161
    Inglewood, California 90301, United States
  • Investigational Site Number 840194
    Laguna Hills, California 92653, United States
  • Investigational Site Number 840710
    Laguna Hills, California 92653, United States
  • Investigational Site Number 840204
    Lancaster, California 93534, United States
  • Investigational Site Number 840371
    Los Angeles, California 90017, United States
  • Investigational Site Number 840310
    Los Angeles, California 90036, United States
  • Investigational Site Number 840504
    Los Angeles, California 90036, United States
  • Investigational Site Number 840340
    Los Angeles, California 90057, United States
  • Investigational Site Number 840309
    Los Gatos, California 95032, United States
  • Investigational Site Number 840256
    North Hollywood, California 91606, United States
  • Investigational Site Number 840015
    Northridge, California 91325, United States
  • Investigational Site Number 840056
    Norwalk, California 90650, United States
  • Investigational Site Number 840090
    Orange, California 92868, United States
  • Investigational Site Number 840078
    Palm Springs, California 92262, United States
  • Investigational Site Number 840791
    Palmdale, California 93551, United States
  • Investigational Site Number 840216
    Paramount, California 90723, United States
  • Investigational Site Number 840413
    Pomona, California 91767, United States
  • Investigational Site Number 840244
    Port Hueneme, California 93041, United States
  • Investigational Site Number 840162
    San Diego, California 92111-6342, United States
  • Investigational Site Number 840028
    San Diego, California 92117-4961, United States
  • Investigational Site Number 840383
    San Dimas, California 91773, United States
  • Investigational Site Number 840627
    San Jose, California 95148, United States
  • Investigational Site Number 840120
    San Ramon, California 94583, United States
  • Investigational Site Number 840156
    Santa Ana, California 92704, United States
  • Investigational Site Number 840266
    Sherman Oaks, California 91403, United States
  • Investigational Site Number 840091
    Sylmar, California 91342, United States
  • Investigational Site Number 840208
    Thousand Oaks, California 91360, United States
  • Investigational Site Number 840115
    Torrance, California 90505, United States
  • Investigational Site Number 840792
    Torrance, California 90601, United States
  • Investigational Site Number 840612
    Tulare, California 93274, United States
  • Investigational Site Number 840467
    Upland, California 91786, United States
  • Investigational Site Number 840185
    Vista, California 92083, United States
  • Investigational Site Number 840472
    Whittier, California 90606, United States
  • Investigational Site Number 840411
    Aurora, Colorado 80014, United States
  • Investigational Site Number 840596
    Denver, Colorado 80209, United States
  • Investigational Site Number 840170
    Denver, Colorado 80246, United States
  • Investigational Site Number 840188
    Englewood, Colorado 80113, United States
  • Investigational Site Number 840329
    Littleton, Colorado 80127, United States
  • Investigational Site Number 840728
    Littleton, Colorado 80128, United States
  • Investigational Site Number 840687
    Northglenn, Colorado 80234, United States
  • Investigational Site Number 840643
    Aventura, Florida 33180, United States
  • Investigational Site Number 840652
    Boca Raton, Florida 33433, United States
  • Investigational Site Number 840449
    Bradenton, Florida 34209, United States
  • Investigational Site Number 840081
    Cooper City, Florida 33024, United States
  • Investigational Site Number 840027
    Coral Gables, Florida 33134, United States
  • Investigational Site Number 840446
    Coral Gables, Florida 33134, United States
  • Investigational Site Number 840407
    Cutler Bay, Florida 33157, United States
  • Investigational Site Number 840083
    Doral, Florida 33122, United States
  • Investigational Site Number 840141
    Fleming Island, Florida 32003, United States
  • Investigational Site Number 840035
    Fort Lauderdale, Florida 33316, United States
  • Investigational Site Number 840068
    Fort Lauderdale, Florida 33316, United States
  • Investigational Site Number 840145
    Hialeah, Florida 33016, United States
  • Investigational Site Number 840142
    Jacksonville, Florida 322078334, United States
  • Investigational Site Number 840352
    Jacksonville, Florida 32216, United States
  • Investigational Site Number 840021
    Jupiter, Florida 33458, United States
  • Investigational Site Number 840639
    Kissimmee, Florida 34741, United States
  • Investigational Site Number 840640
    Kissimmee, Florida 34741, United States
  • Investigational Site Number 840777
    Lake Clarke Shores, Florida 33406, United States
  • Investigational Site Number 840362
    Margate, Florida 33063, United States
  • Investigational Site Number 840221
    Miami Lakes, Florida 33016, United States
  • Investigational Site Number 840303
    Miami Lakes, Florida 33326, United States
  • Investigational Site Number 840002
    Miami, Florida 33015, United States
  • Investigational Site Number 840012
    Miami, Florida 33126, United States
  • Investigational Site Number 840698
    Miami, Florida 33126, United States
  • Investigational Site Number 840102
    Miami, Florida 33136, United States
  • Investigational Site Number 840209
    Miami, Florida 33142, United States
  • Investigational Site Number 840014
    Miami, Florida 33144, United States
  • Investigational Site Number 840128
    Miami, Florida 33155, United States
  • Investigational Site Number 840143
    Miami, Florida 33155, United States
  • Investigational Site Number 840349
    Miami, Florida 33155, United States
  • Investigational Site Number 840758
    Miami, Florida 33155, United States
  • Investigational Site Number 840690
    Miami, Florida 33166, United States
  • Investigational Site Number 840415
    Miami, Florida 33174, United States
  • Investigational Site Number 840197
    Miami, Florida 33185, United States

Showing the first 100 of 427 sites across 2 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Anderson J, Meneghini L, Hinnen D, Gill J, Coudert M, Evenou P, Munshi M. Target attainment in insulin-naive patients at high risk for hypoglycemia: Results from ACHIEVE Control. J Diabetes Complications. 2021 Apr;35(4):107831. doi: 10.1016/j.jdiacomp.2020.107831. Epub 2020 Dec 31. PubMed 33509703 ↗
  • Oster G, Sullivan SD, Dalal MR, Kazemi MR, Rojeski M, Wysham CH, Sung J, Johnstone B, Cali AM, Wei LJ, Traylor L, Anhalt H, Hull M, Van Vleet J, Meneghini LF. Achieve control: a pragmatic clinical trial of insulin glargine 300 U/mL versus other basal insulins in insulin-naive patients with type 2 diabetes. Postgrad Med. 2016 Nov;128(8):731-739. doi: 10.1080/00325481.2016.1241663. Epub 2016 Oct 24. PubMed 27690710 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2015 to primary completion in Mar 2018, 32 months.

Results were first posted in May 2019, 1 year 1 month after primary completion.

Of 132 industry-sponsored phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 28. This study's 32 months is above that.

Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2015
First posted
May 21, 2015
StartActual
Jun 16, 2015
Primary completionActual
Mar 2, 2018
CompletionActual
Aug 9, 2018
Results first posted
May 1, 2019
Last update
Sep 10, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02451137
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
May 21, 2015
Start date
Jun 16, 2015
Primary completion
Mar 2, 2018
Completion
Aug 9, 2018
Results posted
May 1, 2019
Last update
Sep 10, 2019

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin Glargine

Start the discussion